Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
39.21
-0.33 (-0.83%)
At close: Jun 5, 2025, 4:00 PM
39.10
-0.11 (-0.28%)
After-hours: Jun 5, 2025, 4:38 PM EDT
Sarepta Therapeutics Stock Forecast
Stock Price Forecast
According to 23 professional analysts, the 12-month price target for Sarepta Therapeutics stock ranges from a low of $40 to a high of $230. The average analyst price target of $125.43 forecasts a 219.89% increase in the stock price over the next year.
Price Target: $125.43 (+219.89%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Sarepta Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 5 | 6 | 6 |
| Buy | 13 | 12 | 11 | 12 | 12 | 12 |
| Hold | 1 | 1 | 3 | 4 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 2 | 2 | 2 | 1 | 0 | 0 |
| Total | 22 | 21 | 21 | 22 | 23 | 23 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $40 | Hold | Reiterates | $40 | +2.01% | May 22, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $169 → $84 | Buy | Maintains | $169 → $84 | +114.23% | May 20, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $115 → $100 | Buy | Maintains | $115 → $100 | +155.04% | May 8, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $87 → $58 | Hold | Maintains | $87 → $58 | +47.92% | May 7, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $178 → $100 | Strong Buy | Maintains | $178 → $100 | +155.04% | May 7, 2025 |
Financial Forecast
Revenue This Year
2.61B
from 1.90B
Increased by 37.38%
Revenue Next Year
2.95B
from 2.61B
Increased by 13.05%
EPS This Year
-1.94
from 2.34
EPS Next Year
6.59
from -1.94
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.0B | 3.9B | 4.0B | ||
| Avg | 2.6B | 3.0B | 3.2B | ||
| Low | 2.3B | 2.3B | 1.7B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 55.8% | 50.7% | 35.3% | ||
| Avg | 37.4% | 13.1% | 7.2% | ||
| Low | 21.3% | -12.6% | -41.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.01 | 14.18 | 15.27 | ||
| Avg | -1.94 | 6.59 | 9.31 | ||
| Low | -5.63 | 1.80 | 1.11 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 71.5% | - | 131.8% | ||
| Avg | - | - | 41.4% | ||
| Low | - | - | -83.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.